Co-Diagnostics, Inc. Stock

Equities

CODX

US1897631057

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
1.14 USD -0.87% Intraday chart for Co-Diagnostics, Inc. 0.00% -14.29%
Sales 2024 * 5.82M Sales 2025 * - Capitalization 35.95M
Net income 2024 * -31M Net income 2025 * - EV / Sales 2024 * 6.17 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-1.16 x
P/E ratio 2025 *
-
Employees 155
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.87%
Current month+1.79%
1 month+2.24%
3 months-10.94%
6 months+4.59%
Current year-14.29%
More quotes
1 week
1.09
Extreme 1.091
1.19
1 month
1.07
Extreme 1.0689
1.29
Current year
1.02
Extreme 1.02
1.50
1 year
0.98
Extreme 0.975
1.89
3 years
0.98
Extreme 0.975
11.82
5 years
0.69
Extreme 0.694
30.99
10 years
0.69
Extreme 0.694
30.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 13-04-17
Director of Finance/CFO 48 21-02-21
Chief Tech/Sci/R&D Officer - 22-10-31
Members of the board TitleAgeSince
General Counsel 77 14-10-31
Director/Board Member 79 17-04-30
Chief Executive Officer 70 13-04-17
More insiders
Date Price Change Volume
24-04-24 1.14 -0.87% 32 978
24-04-23 1.15 0.00% 10,270
24-04-22 1.15 0.00% 26,328
24-04-19 1.15 -0.86% 18,433
24-04-18 1.16 +1.75% 216,760

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.15 USD
Average target price
2.5 USD
Spread / Average Target
+117.39%
Consensus